Protalix BioTherapeutics
PLX
PLX
47 hedge funds and large institutions have $159M invested in Protalix BioTherapeutics in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
0% more funds holding
Funds holding: 47 → 47 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
95% less call options, than puts
Call options by funds: $210K | Put options by funds: $3.84M
Holders
47
Holding in Top 10
1
Calls
$210K
Puts
$3.84M
Top Buyers
1 | +$3.48M | |
2 | +$2.51M | |
3 | +$1.42M | |
4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.41M |
5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$1.31M |
Top Sellers
1 | -$784K | |
2 | -$253K | |
3 | -$237K | |
4 |
Morgan Stanley
New York
|
-$233K |
5 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$226K |